Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of TNBC — TOWARDS-II  

Breast Cancer Recurrent Clinical Trial

Official title: Towards Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of Triple Negative Breast Cancer

Status Recruiting

Clinical Trial Summary

This is a prospective phase 2 study to use Functional Precision Oncology (FPO) to predict, prevent and treat early metastatic recurrence in subjects with HR-low/Her2 negative or triple negative breast cancer.

Clinical Trial Description

The aim of this clinical trial is to extend the findings of the investigators' first observational clinical study titled "Towards personalized medicine: patient derived breast tumor grafts as predictors of relapse and response to therapy" (TOWARDS-I). In TOWARDS-II, the investigators will develop patient derived models (PDMs), comprising patient derived xenografts (PDXs) and organoids (PDO and PDxO), from patients newly diagnosed with local or locally advanced hormone receptor-low/Her2 negative or triple negative breast cancer. The investigators will prospectively evaluate the correlation between PDX engraftment with recurrence. Using PDMs, the investigators will perform genomic studies and functional drug screens (FPO). Upon disease recurrence, the investigators will return the results to the physician with the intent to inform treatment selection. ;

Related Conditions & MeSH terms

• Breast Cancer Recurrent
• Breast Neoplasms
• Recurrence

• NCT number: NCT05464082
• Study type: Interventional
• Source: University of Utah
• Contact: Janna Espinosa
• Phone: 801-585-0571
• Email: janna.espinosa@hci.utah.edu
• Status: Recruiting
• Phase: Phase 2
• Start date: January 6, 2023
• Completion date: September 30, 2027